REG-Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Globe Newswire•26/10/2026•17:05 ET
0
Key Highlights
- ➤Q3 2026 financial results scheduled for November 5, 2026
- ➤Management conference call set for 4:30 pm ET on November 5
- ➤Nyxoah (NYXH) FDA-approved Genio system for OSA treatment
- ➤FDA approval in August 2025 included CCC patients in indications warning
Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.
Get started
Create a free account to read the full story.